Optimer binders against three therapeutic targets to support drug validation and potential clinical trial applications ...

The Company, under the leadership of its new CEO, Diede van den Ouden, who joined in the June 2025, is currently undertaking a strategic restructuring with the goal of providing the financial ...

Aptamer Group plc, the developer of next-generation synthetic binders for the life sciences industry, today announced a new ...

Aptamer Group Plc ( ($GB:APTA) ) has provided an update. Aptamer Group has secured a significant new contract with a top five pharmaceutical ...

The semi-annual report is available on the website of TME Pharma.

RESEARCH TRIANGLE, N.C., Oct. 22, 2025 /PRNewswire/ -- Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing the first reversible thrombolytic therapy for acute ischemic ...

Orbital Therapeutics, an RNA firm launched just 3 years ago by longtime Alnylam Pharmaceuticals head John Maraganore alongside entrepreneurs from Stanford University and Arch Venture Partners, is ...

A new RNA biotech has risen with a $200 million series A in the tank and a team of seasoned biotech chefs ready to light the burners. Soufflé Therapeutics will cook up siRNA medicines that are ...

TOKYO--(BUSINESS WIRE)--RIBOMIC, Inc. (TOKYO:4591), a clinical-stage pharmaceutical company specializing in aptamer therapeutics, has conducted a Phase 2 clinical trial of umedaptanib pegol (anti-FGF2 ...

In a quest to develop new antiviral drugs for COVID-19 and other diseases, a collaboration led by scientists at The Wertheim UF Scripps Institute has identified a potential new drug against the virus ...

For the first time, scientists can view RNA molecules directly inside cells and tissue in minute detail and across the entire human genome concurrently, thanks to new technology created by a Yale ...